• Baxter, E.J., Scott, L.M., Campbell, P.J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G.S., Bench, A.J., Boyd, E.M., Curtin, N., Scott, M.A., Erber, W.N. & Green, A.R. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 365, 10541061.
  • Delhommeau, F., Dupont, S., Tonetti, C., Masse, A., Godin, I., Le Couedic, J.P., Debili, N., Saulnier, P., Casadevall, N., Vainchenker, W. & Giraudier, S. (2006) Evidence that the JAK2 G1849T (V617F) mutation occurs in a lympho-myeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood, Sep 5; [Epub ahead of print].
  • Jones, A.V., Kreil, S., Zoi, K., Waghorn, K., Curtis, C., Zhang, L., Score, J., Seear, R., Chase, A.J., Grand, F.H., White, H., Zoi, C., Loukopoulos, D., Terpos, E., Vervessou, E.C., Schultheis, B., Emig, M., Ernst, T., Lengfelder, E., Hehlmann, R., Hochhaus, A., Oscier, D., Silver, R.T., Reiter, A. & Cross, N.C. (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood, 106, 21622168.
  • McClure, R., Mai, M. & Lasho, T. (2006) Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders. Leukemia, 20, 168171.
  • Passamonti, F., Rumi, E., Pietra, D., Della Porta, M.G., Boveri, E., Pascutto, C., Vanelli, L., Arcaini, L., Burcheri, S., Malcovati, L., Lazzarino, M. & Cazzola, M. (2006) Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood, 107, 36763682.
  • Sidon, P., El Housni, H., Dessars, B. & Heimann, P. (2006) The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors. Leukemia, 20, 1622.
  • Xu, X., Zhang, Q., Luo, J., Xing, S., Li, Q., Krantz, S.B., Fu, X. & Zhao, Z.J. (2006) JAK2V617F: prevalence in a large Chinese hospital population. Blood, Aug 31; [Epub ahead of print].